---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/100000000838091.md"
description: "$Eli Lilly(LLY.US) (+5% today) now has two of the top 10 selling drugs in the world:  #1 Mounjaro for type 2 diabetes (est 2026 Revs $36B), and #6 Zepbound for weight loss (est 2026 Revs $18B), plus 6 other drugs with more than $1B in expected 2026 revenues.   When a pharma rep has a product platform that deep, it gives the sales rep a huge advantage to sell in both new delivery forms for existing treatments (e.g. LLY’s GLP-1 weight loss pill Foundayo) and for new treatments (LLY’s Kisunla for Alzheimer’s, which should generate $600M sales in FY’2026).  At 35x 2026 Adj EPS, LLY is certainly not cheap vs +12-15% long-term rev growth and +18-20% EPS growth but it’s a great play on weight loss, type 2 diabetes, and aging."
datetime: "2026-08-05T14:21:58.000Z"
locales:
  - [en](https://longbridge.com/en/topics/100000000838091.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/100000000838091.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/100000000838091.md)
author: "[Gary Black Tracker](https://longbridge.com/en/profiles/17077344.md)"
generator: "portal-rs"
---

# $Eli Lilly(LLY.US) (+5% today) now has two of the …


### Related Stocks

- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**